Embryonic Stem Cells
Embryonic stem cells (ESCs) are pluripotent stem cells derived from the inner cell mass of a blastocyst, an early-stage pre-implantation embryo. Human embryos reach the blastocyst stage 4–5 days post fertilization, at which time they consist of 50–150 cells. Isolating the inner cell mass (embryoblast) using immunosurgery results in destruction of the blastocyst, a process which raises ethical issues, including whether or not embryos at the pre-implantation stage have the same moral considerations as embryos in the post-implantation stage of development. — Wikipedia
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Earliest trial started Jan 31, 2020 (NCT04232592)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Stem CellSupplementation
Stem Cell supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEmbryonic stem cell ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04610359 | Phase 1 | Oct 20, 2020 | MIRAE CELL BIO, University of Ulsan |
| NCT04232592 | Phase 1 | Jan 31, 2020 | Chinese Academy of Medical Sciences, Huazhong University of Science and Technology |
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2020 |
| MIRAE CELL BIO | For profit | 1 | 0 | 1 | 2020 |
| University of Ulsan | Academic/Hospital | 1 | 1 | 1 | 2020 |